Interpretation
The outcomes of this trial suggest that successful treatment of ID can occur with a single 1000mg dose, with no adverse outcomes for antenatal progression, neonatal or child outcomes. This represents an effective treatment modality to shield from the detrimental short- and potential long-term impacts of ID and IDA. Further, adequate iron stores have the potential to positively impact maternal mental health during pregnancy and post-partum; maternal mental health outcomes collected during this trial will be the subject of a subsequent article. Further studies will help to optimise IVI dose, which may be particularly relevant to those countries where 1000mg is not currently routinely used.